Atlas Venture, an early stage venture capital firm investing in biotech innovation, has closed its thirteenth fund, raising USD450 million in an oversubscribed fundraise.
With Fund XIII, Atlas Venture will continue working alongside talented entrepreneurs to create and invest in a new set of biotech companies aimed at delivering impactful medicines to patients.
Atlas Venture has been building and investing in innovative biotech startups for more than two decades. Since 2015, Atlas Venture has raised over USD2 billion and has created and/or invested in over 50 biotech companies. In addition to Fund XIII, Atlas is also investing from Opportunity Fund II, a USD300 million fund raised in 2021 to support portfolio companies as they raise subsequent financings and advance therapeutic programs. Alongside Atlas partner Jason Rhodes, the six investing partners in Fund XIII also include Kevin Bitterman, Bruce Booth, Jean-François Formela, Michael Gladstone, and David Grayzel.
Read more: Private Equity Wire
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.